Literature DB >> 21353160

Interaction of 2-Gy equivalent dose and margin status in perioperative high-dose-rate brachytherapy.

Rafael Martínez-Monge1, Mauricio Cambeiro, Marta Moreno, Miren Gaztañaga, Mikel San Julián, Juan Alcalde, Matías Jurado.   

Abstract

PURPOSE: To determine patient, tumor, and treatment factors predictive of local control (LC) in a series of patients treated with either perioperative high-dose-rate brachytherapy (PHDRB) alone (Group 1) or with PHDRB combined with external-beam radiotherapy (EBRT) (Group 2). PATIENT AND METHODS: Patients (n = 312) enrolled in several PHDRB prospective Phase I-II studies conducted at the Clínica Universidad de Navarra were analyzed. Treatment with PHDRB alone, mainly because of prior irradiation, was used in 126 patients to total doses of 32 Gy/8 b.i.d. or 40 Gy/10 b.i.d. treatments after R0 or R1 resections. Treatment with PHDRB plus EBRT was used in 186 patients to total doses of 16 Gy/4 b.i.d. or 24 Gy/6 b.i.d. treatments after R0 or R1 resections along with 45 Gy of EBRT with or without concomitant chemotherapy.
RESULTS: No dose-margin interaction was observed in Group 1 patients. In Group 2 patients there was a significant interaction between margin status and 2-Gy equivalent (Eq2Gy) dose (p = 0.002): (1) patients with negative margins had 9-year LC of 95.7% at Eq2Gy = 62.9Gy; (2) patients with close margins of >1 mm had 9-year LC of 92.4% at Eq2Gy = 72.2Gy, and (3) patients with positive/close <1-mm margins had 9-year LC of 68.0% at Eq2Gy = 72.2Gy.
CONCLUSIONS: Two-gray equivalent doses ≥70 Gy may compensate the effect of close margins ≥1 mm but do not counterbalance the detrimental effect of unfavorable (positive/close <1 mm) resection margins. No dose-margin interaction is observed in patients treated at lower Eq2Gy doses ≤50 Gy with PHDRB alone.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21353160     DOI: 10.1016/j.ijrobp.2009.12.023

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

Review 1.  The role of brachytherapy in the treatment of squamous cell carcinoma of the head and neck.

Authors:  Małgorzata Wierzbicka; Anna Bartochowska; Vratislav Strnad; Primož Strojan; William M Mendenhall; Louis B Harrison; Alessandra Rinaldo; Puja Sahai; Susanne Wiegand; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-22       Impact factor: 2.503

Review 2.  INTERACTS (INTErventional Radiotherapy ACtive Teaching School) consensus conference on sarcoma interventional radiotherapy (brachytherapy) endorsed by AIRO (Italian Association of Radiotherapy and Clinical Oncology).

Authors:  Luca Tagliaferri; Andrea Vavassori; Valentina Lancellotta; Vitaliana De Sanctis; Cristiana Vidali; Calogero Casà; Cynthia Aristei; Domenico Genovesi; Barbara Alicja Jereczek-Fossa; Alessio Giuseppe Morganti; György Kovács; Jose Luis Guinot; Agata Rembielak; Daniela Greto; Maria Antonietta Gambacorta; Vincenzo Valentini; Vittorio Donato; Renzo Corvò; Stefano Maria Magrini; Lorenzo Livi
Journal:  J Contemp Brachytherapy       Date:  2020-08-21

3.  Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma.

Authors:  Arash O Naghavi; Ricardo J Gonzalez; Jacob G Scott; John E Mullinax; Yazan A Abuodeh; Youngchul Kim; Odion Binitie; Kamran A Ahmed; Marilyn M Bui; Amarjit S Saini; Jonathan S Zager; Matthew C Biagioli; Douglas Letson; Louis B Harrison; Daniel C Fernandez
Journal:  Brachytherapy       Date:  2016-05-12       Impact factor: 2.362

Review 4.  Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy.

Authors:  György Kovács
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

5.  Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic.

Authors:  Pranshu Mohindra; Sushil Beriwal; Mitchell Kamrava
Journal:  Brachytherapy       Date:  2020-05-01       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.